Literature DB >> 18469732

Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers.

Jobst Henker1, Martin W Laass, Boris M Blokhin, Vitaliy G Maydannik, Yuriy K Bolbot, Martina Elze, Corinna Wolff, Armin Schreiner, Jürgen Schulze.   

Abstract

BACKGROUND: Administering probiotics can prevent or cure some forms of diarrhea. The efficacy of probiotic Escherichia coli Nissle 1917 (EcN) in infants and toddlers with diarrhea >4 days was tested by a double-blind trial.
METHODS: One hundred fifty-one children aged 1-47 months with nonspecific diarrhea were randomized to receive either EcN suspension (N = 75) or placebo (N = 76). Diarrhea had to meet the following definition: >3 watery or loose nonbloody stools in 24 hours of a diarrheal episode persisting for >4 consecutive days but < or =14 days. All children were well nourished or only moderately malnourished, mildly dehydrated, and received oral rehydration at study commencement. They were treated orally with 1-3 mL EcN suspension (1 mL contains 10 viable cells) or placebo daily for 21 days. Primary objective was to confirm a better response rate (reduction of daily stool frequency to < or =3 watery or loose stools over > or =4 days) with EcN.
RESULTS: The 7-day response was higher for the EcN group than placebo (EcN 78.7%, placebo 59.2%). Significant differences were observed on days 14 (EcN 93.3%, placebo 65.8%, P = 0.0017) and 21 (EcN 98.7%, placebo 71.1%, P < 0.001). Kaplan-Meier survival analysis resulted in a significant difference of 3.3 days between the groups (P < 0.0001); median time to response for EcN was 2.4 and 5.7 for placebo. EcN was safe and well tolerated.
CONCLUSIONS: In the conditions of this trial EcN was a suitable remedy for diarrhea >4 days in young children.

Entities:  

Mesh:

Year:  2008        PMID: 18469732     DOI: 10.1097/INF.0b013e318169034c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  32 in total

Review 1.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

Review 2.  Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.

Authors:  Franco Scaldaferri; Viviana Gerardi; Francesca Mangiola; Loris Riccardo Lopetuso; Marco Pizzoferrato; Valentina Petito; Alfredo Papa; Jovana Stojanovic; Andrea Poscia; Giovanni Cammarota; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 3.  The Traveling Microbiome.

Authors:  Mark S Riddle; Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

4.  Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis.

Authors:  Sumei Sha; Bin Xu; Xiangyun Kong; Ni Wei; Jian Liu; Kaichun Wu
Journal:  Inflamm Res       Date:  2014-08-14       Impact factor: 4.575

5.  CRISPR-based curing and analysis of metabolic burden of cryptic plasmids in Escherichia coli Nissle 1917.

Authors:  Halimatun S Zainuddin; Yanfen Bai; Thomas J Mansell
Journal:  Eng Life Sci       Date:  2019-06-03       Impact factor: 2.678

6.  Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.

Authors:  Sylvia Kleta; Marcel Nordhoff; Karsten Tedin; Lothar H Wieler; Rafal Kolenda; Sibylle Oswald; Tobias A Oelschlaeger; Wilfried Bleiss; Peter Schierack
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

7.  Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.

Authors:  Yunlei Zhang; Youming Zhang; Liqiu Xia; Xiangli Zhang; Xuezhi Ding; Fu Yan; Feng Wu
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

8.  A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.

Authors:  B Arribas; M E Rodríguez-Cabezas; D Camuesco; M Comalada; E Bailón; P Utrilla; A Nieto; A Concha; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2009-05-26       Impact factor: 8.739

9.  Differential Effects of Escherichia coli Nissle and Lactobacillus rhamnosus Strain GG on Human Rotavirus Binding, Infection, and B Cell Immunity.

Authors:  Sukumar Kandasamy; Anastasia N Vlasova; David Fischer; Anand Kumar; Kuldeep S Chattha; Abdul Rauf; Lulu Shao; Stephanie N Langel; Gireesh Rajashekara; Linda J Saif
Journal:  J Immunol       Date:  2016-01-22       Impact factor: 5.422

10.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.